ALKS Alkermes plc

32.82
-0.95  -3%
Previous Close 33.77
Open 33.22
Price To Book 4.43
Market Cap 5099663069
Shares 155,382,787
Volume 1,279,955
Short Ratio
Av. Daily Volume 992,210

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181208723
  2. 8-K - Current report 181207009
  3. 8-K - Current report 181174181
  4. 8-K - Current report 181155120
  5. 8-K - Current report 181145545

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Schizophrenia
Phase 3 initiation announced June 8, 2017.
ALKS 3831 - ENLIGHTEN-Early
Schizophrenia - young adults
Phase 3 data released November 29, 2018 met co-primary endpoints. NDA filing due mid-2019.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
NDA filing due 4Q 2018.
ALKS 8700 (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
PDUFA date of January 31, 2019. Advisory Committee Meeting November 1, 2018 voted 2-21 against recommending approval.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
Phase 1 initial data at SITC November 9, 2018.
ALKS 4230
Solid tumors
Phase 3 data due 1H 2019.
Aristada and Invega Sustenna
Schizophrenia

Latest News

  1. Need To Know: Alkermes plc (NASDAQ:ALKS) Insiders Have Been Selling Shares
  2. ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  3. New Research Coverage Highlights Tractor Supply, Shaw Communications, Alkermes plc, Jacobs Engineering Group, Eastman Chemical, and Varian Medical — Consolidated Revenues, Company Growth, and Expectations for 2018
  4. Alkermes- A New Tool in Treating Schizophrenia
  5. See what the IHS Markit Score report has to say about Alkermes Plc.
  6. ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  7. Alkermes schizophrenia drug keeps weight gain side effect in check
  8. Alkermes touts 'positive' schizophrenia drug data, but investors not impressed
  9. Alkermes reports positive results in trial of schizophrenia treatment that reduces weight gain
  10. Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
  11. See what the IHS Markit Score report has to say about Alkermes PLC.
  12. Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound?
  13. INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  14. INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  15. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc, Inc. (ALKS)
  16. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation of Alkermes plc - ALKS
  18. EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS
  19. Just How Bad Is Alkermes' Depression Drug Setback?
  20. Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

SEC Filings

  1. CT ORDER - Confidential treatment order 181208723
  2. 8-K - Current report 181207009
  3. 8-K - Current report 181174181
  4. 8-K - Current report 181155120
  5. 8-K - Current report 181145545
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181133360
  7. 8-K - Current report 181133281
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181113467
  9. S-8 - Securities to be offered to employees in employee benefit plans 18971895
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18970427